

Haematologica  
HAEMATOL/2019/238691  
Version 1  
BIRC3 mutations in CLL – uncommon and unfavorable

Eugen Tausch and Stephan Stilgenbauer

Disclosures: ET reports financial and non-financial support from Abbvie, Roche and Janssen pharma outside the submitted work. StSt reports financial and non-financial support from AbbVie, Hoffmann La-Roche, Amgen, AstraZeneca, Celgene, Gilead, GSK, Janssen, Novartis, Pharmacyclics and Sunesis outside the submitted work.

Contributions: ET and StSt wrote the manuscript